Tumor immunotherapy in melanoma: On the dawn of a new era?

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Since discovery of the first melanoma-associated tumor antigen, great strides have been made in elucidating the cellular and molecular basis for the adaptive immune response to human cancers, including melanoma. Despite this understanding and its application to melanoma patients in the form of various tumor vaccines, advanced-stage melanoma continues to be a devastating disease, associated with significant morbidity and mortality. Recent advances in melanoma immunotherapy and novel T-cell co-stimulation-based strategies that have shown promise in preclinical studies are discussed. While many current antigenbased approaches, either in the form of active or passive immunotherapy, may generate a tumor-specific T-cell response, the overall response rate observed clinically in most cohorts of melanoma patients has been suboptimal. Therefore, antigenindependent strategies capable of overcoming barriers to tumor eradication, such as tumor-mediated suppression, tumor evasion or self-tolerance, may represent promising new additions to the current arsenal of tumor vaccines.

Original languageEnglish (US)
Pages (from-to)70-78
Number of pages9
JournalCurrent Opinion in Molecular Therapeutics
Volume9
Issue number1
StatePublished - Feb 2007

Fingerprint

Immunotherapy
Melanoma
Neoplasms
Cancer Vaccines
T-Lymphocytes
Self Tolerance
Active Immunotherapy
Passive Immunization
Adaptive Immunity
Neoplasm Antigens
Morbidity
Mortality

Keywords

  • Adoptive immunotherapy
  • CD137
  • Co-stimulation
  • Cytotoxic T-lymphocyte A4
  • Melanoma
  • Peptide vaccine
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Tumor immunotherapy in melanoma : On the dawn of a new era? / Wilcox, Ryan; Markovic, Svetomir Nenad.

In: Current Opinion in Molecular Therapeutics, Vol. 9, No. 1, 02.2007, p. 70-78.

Research output: Contribution to journalArticle

@article{cfe41c2c163c4682a64cdf5c7c145c02,
title = "Tumor immunotherapy in melanoma: On the dawn of a new era?",
abstract = "Since discovery of the first melanoma-associated tumor antigen, great strides have been made in elucidating the cellular and molecular basis for the adaptive immune response to human cancers, including melanoma. Despite this understanding and its application to melanoma patients in the form of various tumor vaccines, advanced-stage melanoma continues to be a devastating disease, associated with significant morbidity and mortality. Recent advances in melanoma immunotherapy and novel T-cell co-stimulation-based strategies that have shown promise in preclinical studies are discussed. While many current antigenbased approaches, either in the form of active or passive immunotherapy, may generate a tumor-specific T-cell response, the overall response rate observed clinically in most cohorts of melanoma patients has been suboptimal. Therefore, antigenindependent strategies capable of overcoming barriers to tumor eradication, such as tumor-mediated suppression, tumor evasion or self-tolerance, may represent promising new additions to the current arsenal of tumor vaccines.",
keywords = "Adoptive immunotherapy, CD137, Co-stimulation, Cytotoxic T-lymphocyte A4, Melanoma, Peptide vaccine, Tumor immunotherapy",
author = "Ryan Wilcox and Markovic, {Svetomir Nenad}",
year = "2007",
month = "2",
language = "English (US)",
volume = "9",
pages = "70--78",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "1",

}

TY - JOUR

T1 - Tumor immunotherapy in melanoma

T2 - On the dawn of a new era?

AU - Wilcox, Ryan

AU - Markovic, Svetomir Nenad

PY - 2007/2

Y1 - 2007/2

N2 - Since discovery of the first melanoma-associated tumor antigen, great strides have been made in elucidating the cellular and molecular basis for the adaptive immune response to human cancers, including melanoma. Despite this understanding and its application to melanoma patients in the form of various tumor vaccines, advanced-stage melanoma continues to be a devastating disease, associated with significant morbidity and mortality. Recent advances in melanoma immunotherapy and novel T-cell co-stimulation-based strategies that have shown promise in preclinical studies are discussed. While many current antigenbased approaches, either in the form of active or passive immunotherapy, may generate a tumor-specific T-cell response, the overall response rate observed clinically in most cohorts of melanoma patients has been suboptimal. Therefore, antigenindependent strategies capable of overcoming barriers to tumor eradication, such as tumor-mediated suppression, tumor evasion or self-tolerance, may represent promising new additions to the current arsenal of tumor vaccines.

AB - Since discovery of the first melanoma-associated tumor antigen, great strides have been made in elucidating the cellular and molecular basis for the adaptive immune response to human cancers, including melanoma. Despite this understanding and its application to melanoma patients in the form of various tumor vaccines, advanced-stage melanoma continues to be a devastating disease, associated with significant morbidity and mortality. Recent advances in melanoma immunotherapy and novel T-cell co-stimulation-based strategies that have shown promise in preclinical studies are discussed. While many current antigenbased approaches, either in the form of active or passive immunotherapy, may generate a tumor-specific T-cell response, the overall response rate observed clinically in most cohorts of melanoma patients has been suboptimal. Therefore, antigenindependent strategies capable of overcoming barriers to tumor eradication, such as tumor-mediated suppression, tumor evasion or self-tolerance, may represent promising new additions to the current arsenal of tumor vaccines.

KW - Adoptive immunotherapy

KW - CD137

KW - Co-stimulation

KW - Cytotoxic T-lymphocyte A4

KW - Melanoma

KW - Peptide vaccine

KW - Tumor immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=34047157600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047157600&partnerID=8YFLogxK

M3 - Article

C2 - 17330404

AN - SCOPUS:34047157600

VL - 9

SP - 70

EP - 78

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 1

ER -